Yu-Ligh Liou

Beijing OriginPoly Bio-Tec Co., Ltd, China

Title: DNA methylation detection as a new non-invasive diagnosis technique for cervical cancer

Abstract

The development of invasive cervical cancer is a slow process that can take up to 30 years from initial high-risk type of human papillomavirus (hrHPV) infection, allowing detection and treatment of early-stage disease. Many studies have revealed that DNA screening of hrHPV is superior to cervical cytology in the detection of CIN2 or worse (CIN2+) lesions, which has been used in many countries worldwide. This is particularly important in low- and middle-income countries (LMICs) where the healthcare resource is limited, in association with low accessibility and acceptance for cervical cancer screening. Thus, an effective triage approach with adequate cost-effectiveness is required to screen hrHPV DNA-positive women.

During cervical oncogenesis, aberrant DNA methylation of human host cell genes is tightly associated with dysregulated functions of various tumor-suppressor genes. In 2021, the World Health Organization pointed out that DNA methylation testing can be used as a future detection method for cervical cancer, making the clinical application of DNA methylation a global hotspot. Many studies have reported that high methylation level of Paired Box 1 (PAX1) and Junction Adhesion Molecule 3 (JAM3) are highly correlated with cervical cancer and the methylation level of the genes increases with the grade of cervical intraepithelial neoplasia (CIN). Based on the analysis results of more than 10 thousand data in China, we believe that the PAX1/JAM3 methylation detection can be used for: 1. The triage of hrHPV positive women to CIN2 and worse (CIN2+); 2. The secondary triage on women with mild cytological abnormalities to determine the woman with CIN3+; 3. The cervical cancer screening plan for women with cervix with transformation zone III.

Here, we would like to share and explore our clinical experience in using methylation detection for cervical cancer management with all of experts.

Biography

Yu-Ligh Liou is a researcher at Clinical Precision Medicine Research Center, The First Affiliated Hospital of Guangdong Pharmaceutical University and chief of medical officer at Beijing OriginPoly Bio-Tec Co., Ltd. He is committed to the clinical translational medicine of gynecological disease and the development of expert consensus and guidelines in China. He has over 30 publications and has been serving as an editorial board member or reviewer of reputed Journals.

2nd International Conference on Gynecology and Obstetrics

Yu-Ligh Liou

Title: DNA methylation detection as a new non-invasive diagnosis technique for cervical cancer

Abstract

Biography

Organization Location

Mail us at

Our Social Presence

Call us at